204 related articles for article (PubMed ID: 38471620)
21. Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy.
Hallaj S; Meshkini F; Chaleshtari MG; Ghorbani A; Namdar A; Soleimanpour H; Jadidi-Niaragh F
Cell Immunol; 2019 Nov; 345():103963. PubMed ID: 31445668
[TBL] [Abstract][Full Text] [Related]
22. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
23. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
Hill JA; Seo SK
Blood; 2020 Aug; 136(8):925-935. PubMed ID: 32582924
[TBL] [Abstract][Full Text] [Related]
24. Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice.
Gajra A; Zalenski A; Sannareddy A; Jeune-Smith Y; Kapinos K; Kansagra A
Pharmaceut Med; 2022 Jun; 36(3):163-171. PubMed ID: 35672571
[TBL] [Abstract][Full Text] [Related]
25. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.
Sun W; Jiang Z; Jiang W; Yang R
Cancer Treat Res Commun; 2022; 33():100638. PubMed ID: 36184307
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects.
Zhang PF; Xie D; Li Q
Immunotherapy; 2020 Sep; 12(13):1021-1034. PubMed ID: 32727249
[TBL] [Abstract][Full Text] [Related]
28. Barriers and Opportunities for CAR T-Cell Targeting of Solid Tumors.
Conejo-Garcia JR; Guevara-Patino JA
Immunol Invest; 2022 Nov; 51(8):2215-2225. PubMed ID: 35797428
[TBL] [Abstract][Full Text] [Related]
29. Challenges and new technologies in adoptive cell therapy.
Zhang P; Zhang G; Wan X
J Hematol Oncol; 2023 Aug; 16(1):97. PubMed ID: 37596653
[TBL] [Abstract][Full Text] [Related]
30. Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects.
Qian S; Villarejo-Campos P; Guijo I; Hernández-Villafranca S; García-Olmo D; González-Soares S; Guadalajara H; Jiménez-Galanes S; Qian C
Front Immunol; 2022; 13():841425. PubMed ID: 35401510
[TBL] [Abstract][Full Text] [Related]
31. CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities.
Akhoundi M; Mohammadi M; Sahraei SS; Sheykhhasan M; Fayazi N
Cell Oncol (Dordr); 2021 Jun; 44(3):495-523. PubMed ID: 33759063
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.
El-Khazragy N; Ghozy S; Emad P; Mourad M; Razza D; Farouk YK; Mohamed NA; Ahmed MK; Youssef T; Bahnasawy YM; Elmasery S
Immunotherapy; 2020 Dec; 12(18):1341-1357. PubMed ID: 33148070
[TBL] [Abstract][Full Text] [Related]
33. Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety.
Halim L; Ajina A; Maher J
Best Pract Res Clin Haematol; 2018 Jun; 31(2):117-125. PubMed ID: 29909912
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524
[TBL] [Abstract][Full Text] [Related]
35. Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.
Esmaeilzadeh A; Hadiloo K; Jabbari M; Elahi R
Life Sci; 2024 Jan; 337():122381. PubMed ID: 38145710
[TBL] [Abstract][Full Text] [Related]
36. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
37. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
38. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
39. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
Bagley SJ; O'Rourke DM
Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
[TBL] [Abstract][Full Text] [Related]
40. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
